Abstract:Wee1-like protein kinase (Wee1) is a tyrosine kinase that regulates the G(2) checkpoint and prevents entry into mitosis in response to DNA damage. Based on a series of signaling pathways initiated by Wee1, Wee1 has been recognized as a potential target for cancer therapy. To discover potent Wee1 inhibitors with novel scaffolds, ligand-based pharmacophore model has been built based on 101 known Wee1 inhibitors. Then the best pharmacophore model, AADRRR.340, with good partial least square (PLS) statistics (R-2 = 0.9212, Q(2) = 0.7457), was selected and validated. The validated model was used as a three-dimensional (3D) search query for databases virtual screening. The filtered molecules were further analyzed and refined by Lipinski's rule of 5, multiple docking procedures (high throughput virtual screening (HTVS), standard precision (SP), genetic optimization for ligand docking (GOLD), extra precision (XP), and unique quantum polarized ligand docking (QPLD)); absorption, distribution, metabolism, excretion, and toxicity (ADMET) screening; and the Prime/molecular mechanics generalized born surface area (MM-GBSA) method binding free energy calculations. Eight leads were identified as potential Wee1 inhibitors, and a 50 ns molecular dynamics (MD) simulation was carried out for top four inhibitors to predict the stability of ligand-protein complex. Molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) based on MD simulation and the energy contribution per residue to the binding energy were calculated. In the end, three hits with good stabilization and affinity to protein were identified.

Advanced Design, Synthesis, and Evaluation of Highly Selective Wee1 Inhibitors: Enhancing Pharmacokinetics and Antitumor Efficacy

Discovery of Pyrido[4,3-d]pyrimidinone Derivatives as Novel Wee1 Inhibitors

Discovery of Pyrrolo[2,3-D]pyrimidine-based Molecules As a Wee1 Inhibitor Template.

Inhibitors of cell cycle checkpoint target Wee1 kinase – a patent review (2003–2022)

Design, synthesis, and biological evaluation of Wee1 kinase degraders

Pharmacophore Modeling, Multiple Docking, and Molecular Dynamics Studies on Wee1 Kinase Inhibitors

Synthesis and biological evaluation of (2‐aminosulfonylpyridin‐6‐yl)pyrazolopyrimidinone derivatives as Wee1 inhibitors for cancer treatment

Design, Synthesis and Biological Evaluation of Thienopyridinones As Chk1 Inhibitors

Synthetic and Medicinal Chemistry Approaches Toward WEE1 Kinase Inhibitors and Its Degraders

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

WEE1 inhibitor and ataxia telangiectasia and RAD3‐related inhibitor trigger stimulator of interferon gene‐dependent immune response and enhance tumor treatment efficacy through programmed death‐ligand 1 blockade

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1

Discovery of Potential WEE1 Inhibitors Via Hybrid Virtual Screening

Structure-activity relationships of Wee1 inhibitors: A review

Identification of a Rhodium(iii) Complex As a Wee1 Inhibitor Against TP53-mutated Triple-Negative Breast Cancer Cells.

Design, synthesis, and biological evaluation of novel molecules as potent inhibitors of PLK1

Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer

Wee1 Inhibition Can Suppress Tumor Proliferation and Sensitize P53 Mutant Colonic Cancer Cells to the Anticancer Effect of Irinotecan.

Structural and energetic insights into the selective inhibition of PKMYT1 against WEE1

Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by Dntp Starvation